Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

15
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
15
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

24
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
24
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

65
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
65
Development of Human Microbiota01:30

Development of Human Microbiota

61
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
61
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

2.0K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
2.0K
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

143
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal Group B <i>Streptococcus</i> Vaccination: A Three-Country European Consortium to Improve Surveillance and Data Readiness.

Clinical epidemiology·2026
Same author

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Current knowledge and future perspectives on management and prevention of group B streptococcus in neonates and young infants.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Preterm infants: immunity and immunisation.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Methodological framework for the surveillance of healthcare-associated infections in high-risk infants: the NeoIPC surveillance core module protocol.

Antimicrobial resistance and infection control·2026
Same author

Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: May 2, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

13.8K

Neonatal infections: group B streptococcus.

Paul T Heath1, Luke Anthony Jardine

  • 1St. George's University of London, London, UK.

BMJ Clinical Evidence
|March 4, 2014
PubMed
Summary
This summary is machine-generated.

Prophylactic antibiotic treatment for asymptomatic neonates at risk for early-onset group B streptococcus infection is reviewed. Evidence on antibiotic effectiveness and safety for preventing neonatal group B streptococcus infection was evaluated.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

5.5K
Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice
04:18

Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice

Published on: October 10, 2025

735

Related Experiment Videos

Last Updated: May 2, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

13.8K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

5.5K
Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice
04:18

Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice

Published on: October 10, 2025

735

Area of Science:

  • Neonatal infections
  • Bacterial pathogenesis
  • Public health

Background:

  • Group B Streptococcus (GBS) colonization affects 25% of women, posing risks to newborns, including sepsis, pneumonia, and meningitis.
  • Very low-birthweight infants face heightened risks of GBS infection and mortality, even with prompt antibiotic intervention.
  • Late-onset GBS infection (≥7 days) typically presents with fever or meningitis and is less frequently fatal than early-onset disease.

Purpose of the Study:

  • To systematically review the effects of prophylactic treatment in asymptomatic neonates under 7 days old with risk factors for early-onset GBS infection.
  • To evaluate the effectiveness and safety of various interventions, including antibiotics, monitoring, and selective treatment.

Main Methods:

  • Systematic review of medical databases (Medline, Embase, Cochrane Library) up to November 2013.
  • Inclusion of 5 studies meeting predefined criteria.
  • GRADE evaluation of evidence quality for interventions.

Main Results:

  • The review identified 5 studies relevant to the clinical question.
  • GRADE methodology was employed to assess the quality of evidence for the interventions studied.

Conclusions:

  • Information on the effectiveness and safety of different antibiotic regimens, monitoring strategies, and routine antibiotic prophylaxis for GBS is presented.
  • The review synthesizes evidence to inform clinical decisions regarding GBS prevention in at-risk neonates.